Nuclear expression of Ku70/80 is associated with CHEK2 germline mutations in breast cancer

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Ku70/80 protein is crucial for DNA double-strand break repair via the Ku70/80 pathway.
• Ku70/80 inhibitors are potential cancer therapeutics, particularly for cancers overexpressing Ku70/80.
• The relationship between Ku70/80 expression and germline CHEK2 mutations in breast cancer remains uninvestigated.

Purpose of the Study:

• To evaluate Ku70/80 protein expression in breast cancers harboring germline CHEK2 mutations.
• To determine if Ku70/80 expression levels differ between CHEK2-associated and non-associated breast cancers.
• To identify potential patient subgroups suitable for Ku70/80 inhibitor therapy.

Main Methods:

• Immunohistochemistry was performed on tissue microarrays from 225 breast cancer patients.
• Antibodies targeting Ku70/80 protein were used for staining.
• Automated computerized image analysis quantified nuclear Ku70/80 expression.

Main Results:

• The vast majority of breast cancers analyzed exhibited high nuclear Ku70/80 expression.
• A small percentage (3.5%) of tumors showed no Ku70/80 expression.
• Significantly higher nuclear Ku70/80 expression was observed in CHEK2-associated breast cancers compared to CHEK2-non-associated ones (p = 0.009).
• This association remained significant within the estrogen receptor (ER)-positive subgroup (p = 0.03).

Conclusions:

• This is the first study to report an association between Ku70/80 expression and germline CHEK2 mutations in breast cancer.
• Elevated Ku70/80 expression in CHEK2-mutated breast cancers suggests these tumors may be sensitive to Ku70/80 inhibitors.
• CHEK2-associated breast cancer, particularly ER-positive subtypes, represent potential therapeutic targets for Ku70/80 inhibitor treatment.